1 withdrawn. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Withdrawn 1 |
Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab) - Breast Cancer, HER2-positive Breast Cancer | Phase 3 | Withdrawn | Henan Cancer Hospital | 2022-05-11 | 2024-02-26 |
Breast Neoplasms (1) · Pathologic Complete Response (1)
Breast Diseases (1) · Disease Attributes (1) · Neoplasms (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Carboplatin (1) · Docetaxel (1) · Epirubicin (1) · Trastuzumab (1) · pertuzumab (1)
China (1)
Zhenzhen Liu (1)